Comparison of Two Methods of High Frequency Oscillatory Ventilation in Individuals With Acute Respiratory Distress Syndrome

February 26, 2013 updated by: Johns Hopkins University

Phase II Clinical Trial of Two Approaches to High Frequency Oscillatory Ventilation in Acute Respiratory Distress Syndrome

Acute respiratory distress syndrome (ARDS) is a severe lung condition that causes respiratory failure. Individuals with ARDS often require the use of an artificial breathing machine, known as a mechanical ventilator. High frequency oscillatory ventilation (HFOV) is a form of mechanical ventilation that pumps small amounts of air into the lungs at a constant high rate. The purpose of this study is to compare the safety and efficacy of two HFOV methods in individuals with ARDS.

Study Overview

Detailed Description

ARDS is a serious condition that involves lung inflammation and fluid accumulation in the air sacs, leading to low blood oxygen levels and respiratory failure. It is often fatal and affects approximately 160,000 individuals each year in the United States. The main form of treatment for ARDS is delivery of oxygen and a continuous level of pressure to the damaged lungs through mechanical ventilation. However, some methods of mechanical ventilation may cause ventilator-associated lung injury (VALI), a condition that can result from overdistension of the lungs during inspiration or from excessive mechanical forces. VALI can delay or prevent healing from respiratory failure.

HFOV is a mechanical ventilation method that pumps small amounts of air into the lungs at a constant high rate. Because the increments of air are small the likelihood of experiencing overdistension and developing VALI may be reduced. While HFOV is an effective, commonly used ventilation method, there have been no studies that demonstrate the efficacy of HFOV in comparison to the efficacy of conventional mechanical ventilation methods. This study will compare two different HFOV techniques: the HFOV-Hi method, which uses higher airway pressure, and the HFOV-Lo method, which uses lower airway pressure. The purpose of this study is to compare the safety and efficacy of HFOV-Hi, HFOV-Lo, and standard mechanical ventilation methods in individuals with ARDS.

This study will enroll individuals with ARDS at four Baltimore hospitals. Participants will be randomly assigned to receive either HFOV-Hi or HFOV-Lo. All participants will receive their assigned HFOV method for 7 days, until spontaneous breathing occurs, or until death, whichever occurs first. Blood collected at baseline and Days 1 and 3 will be analyzed for markers of inflammation and lung injury. Participants' clinical status will be monitored until they no longer need ventilation and return home, or for up to 60 days while in the hospital. Individuals being treated for ARDS at the participating hospitals who decline to enroll in the study will be asked for permission to monitor their medical progress. These individuals will not take part in any study procedures, but their clinical information will be used for comparison purposes. Additionally, clinical information on other ARDS patients admitted to the hospital over the previous 2 years will be analyzed.

Study Type

Interventional

Enrollment (Actual)

100

Phase

  • Phase 2

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Johns Hopkins Hospital
      • Baltimore, Maryland, United States, 21224
        • Johns Hopkins Bayview Medical Center
      • Baltimore, Maryland, United States
        • University of Maryland Medical Center
    • Ohio
      • Columbus, Ohio, United States
        • Ohio State University Medical Center
    • Texas
      • San Antonio, Texas, United States
        • Wilford Hall Medical Center

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Acute onset of all of the following criteria within a 24-hour period:

    1. Bilateral infiltrates consistent with edema on frontal chest radiograph, with a duration of no more than 7 days
    2. Requires positive pressure ventilation through an endotracheal tube
    3. PaO2/FiO2 less than 200 while receiving positive end-expiratory pressure (PEEP) at more than 8 cm H2O for at least 4 hours, with a duration of no more than 7 days
    4. No clinical evidence of left atrial hypertension

Exclusion Criteria:

  • Weighs less than 35 kilograms
  • Receives more than 5 days of mechanical ventilation during current hospitalization
  • Attending physician declines to give consent for participant to enroll
  • Patient or surrogate declines or is unable to give consent
  • Participation in another interventional study for ARDS in the 30 days prior to study entry
  • Intracranial hypertension
  • Single lung transplant
  • Burns over more than 30% of the surface area of the body
  • Pregnant
  • Sickle (Hgb SS) or sickle-thal (Hgb SC) hemoglobin
  • Pre-existing illness with a life expectancy of 6 months or less
  • Physicians and family are not committed to full support (Exception: An individual will not be excluded if he/she would receive all medical care except for attempts at resuscitation from cardiac arrest)
  • Severe chronic lung disease
  • Prior lung resection
  • More than 72 hours has passed since inclusion criteria were met

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HFOV-Lo
High Frequency Oscillatory Ventilation using lower mean airway pressures and higher FiO2s.
HFOV will be conducted without routine recruitment maneuvers and with a table of mPaw and FiO2s that include relatively low mPaw's.
Experimental: HFOV-Hi
High Frequency Oscillatory Ventilation using higher mean airway pressures
HFOV will be conducted with recruitment maneuvers and with a table of mPaw and FiO2s that include higher mPaw's.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Number of ventilator free days
Time Frame: Measured at 28 days
Measured at 28 days
Changes in plasma concentration of IL-6
Time Frame: Measured at 3 days
Measured at 3 days

Secondary Outcome Measures

Outcome Measure
Time Frame
Number of intensive care unit free days
Time Frame: Measured at 28 days
Measured at 28 days
Mortality
Time Frame: Measured at 60 days
Measured at 60 days
Number of hospital free days
Time Frame: Measured at 60 days
Measured at 60 days
Changes in plasma IL1ra
Time Frame: Measured at 3 days
Measured at 3 days
Changes in plasma IL-1
Time Frame: Measured at 3 days
Measured at 3 days
Changes in plasma IL-10
Time Frame: Measured at 3 days
Measured at 3 days
Changes in plasma surfactant protein D
Time Frame: Measured at 3 days
Measured at 3 days
Changes in plasma von Willebrand factor
Time Frame: Measured at 3 days
Measured at 3 days

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Roy G. Brower, MD, Johns Hopkins University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

November 1, 2006

Primary Completion (Actual)

May 1, 2009

Study Completion (Actual)

June 1, 2009

Study Registration Dates

First Submitted

November 14, 2006

First Submitted That Met QC Criteria

November 14, 2006

First Posted (Estimate)

November 15, 2006

Study Record Updates

Last Update Posted (Estimate)

February 27, 2013

Last Update Submitted That Met QC Criteria

February 26, 2013

Last Verified

July 1, 2009

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Respiratory Distress Syndrome, Adult

Clinical Trials on High Frequency Oscillatory Ventilation-Lo

3
Subscribe